|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:2000
gptkb:FDA
|
|
gptkbp:available_in
|
various strengths
|
|
gptkbp:brand
|
gptkb:Concerta
|
|
gptkbp:category
|
Category C
|
|
gptkbp:clinical_trial
|
long-term safety
ADHD treatment efficacy
comparison with other stimulants
|
|
gptkbp:contraindication
|
gptkb:Ophthalmology
heart problems
hyperthyroidism
history of drug abuse
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:duration
|
up to 12 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:financial_support
|
do not crush or chew
take as directed
|
|
gptkbp:formulation
|
orally disintegrating tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Concerta ODT
|
|
gptkbp:ingredients
|
gptkb:Sannin
|
|
gptkbp:interacts_with
|
antidepressants
MAO inhibitors
antihypertensives
anticonvulsants
|
|
gptkbp:legal_status
|
controlled substance
|
|
gptkbp:lifespan
|
3 to 4 hours
|
|
gptkbp:manufacturer
|
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:patient_population
|
gptkb:children
adults
adolescents
|
|
gptkbp:premiered_on
|
1 to 2 hours
|
|
gptkbp:previous_name
|
gptkb:Sannin
|
|
gptkbp:requires
|
prescription only
|
|
gptkbp:research_focus
|
cognitive enhancement
ADHD management
side effect profile
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
anxiety
headache
nausea
decreased appetite
insomnia
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:used_for
|
treatment of ADHD
|
|
gptkbp:bfsParent
|
gptkb:Sannin
|
|
gptkbp:bfsLayer
|
5
|